Clinical Trials
The use of CS-PHP with melphalan was tested in a formal clinical trial program that included the following studies:
-
Phase 1, single-center [US National Cancer Institute (NCI)], sequential, dose-escalation study to determine the maximum tolerated dose (MTD) of CS-PHP with melphalan in patients with unresectable hepatic metastases from cutaneous or ocular melanoma or other tumor types [
38].
-
Phase 2, open-label, single-center (NCI), nonrandomized, uncontrolled study to examine the efficacy of CS-PHP with melphalan in patients with unresectable primary hepatic malignancies (i.e., HCC or ICC) or unresectable metastatic hepatic malignancies from other tumor types [gastrointestinal adenocarcinoma (primarily CRC), NET, and cutaneous or ocular melanoma] [
39].
-
Phase 3, randomized, controlled, multicenter study (11 active sites in the USA) to evaluate the efficacy, safety, and tolerability of CS-PHP with melphalan compared with best alternative care (BAC) in patients with unresectable hepatic metastases from cutaneous or ocular melanoma [
39]. Patients in the BAC group were allowed to cross over to CS-PHP at the time of documented hepatic progression, provided they continued to meet eligibility criteria for the study at the time of crossover. The primary endpoint for this study was hepatic progression-free survival (hPFS); secondary endpoints were hepatic objective response (hOR) and overall survival (OS).
In the phase 1 study, response was evaluable in 27 patients (Table
1) [
38]. Of 10 patients with ocular melanoma, 50% had an objective tumor response and two had a complete response at 10 and 12 months, respectively. Additionally, two of four patients with hepatic metastases from NET had ongoing partial responses at 5 and 7 months. Dose-limiting toxicities (DLTs), as determined by the investigators, are summarized in Table
2. The MTD of melphalan delivered by CS-PHP was determined to be 3.0 mg/kg since only one patient had a DLT at this dose. All DLTs were events related to bone marrow suppression, including neutropenia, febrile neutropenia, leukopenia, and thrombocytopenia.
Table 1
Treatment responses in phase 1 study of CS-PHP [
38]
Ocular melanoma | 10 | 3 | 7, 9+, 11+ | 2 | 10, 12 | 5 | 50 |
Cutaneous melanoma | 2 | – | – | – | – | 0 | – |
Neuroendocrine | 3 | 2 | 3+, 7+ | – | – | 2 | – |
Colorectal | 1 | – | – | – | – | 0 | – |
Adrenal | 1 | 1 | 10+ | – | – | 1 | – |
Other | 7 | – | – | – | – | 0 | – |
Total | 27* | 6 | – | 2 | – | 8 | 29.6 |
Table 2
DLTs in phase 1 study [
38]
No. of patients with a DLT | 0 | 0 | 1 | 2 |
Decreased neutrophil count | 0 | 0 | – | 2 |
Decreased white blood cell count | 0 | 0 | 1 | 1 |
Decrease platelet count | 0 | 0 | 1 | 2 |
Febrile neutropenia | 0 | 0 | 1 | 1 |
In the phase 2 study (Table
3), objective responses were seen in 75% of ocular melanoma patients, 12.5% of hepatocellular carcinoma patients, and 41.7% of NET patients [
39]. In the last of these cohorts, response varied by type of NET. The hOR rate was 30.8% in patients with pancreatic NET, 66.7% in those with carcinoid NET, and 50.0% in those with other types of NET. All responses were partial responses. An additional 46.2% of patients within the pancreatic NET cohort had stable disease. The most common toxicities were related to bone marrow suppression, the known principal toxicity of melphalan, including thrombocytopenia, anemia, and neutropenia. Most of these events were not associated with clinical sequelae.
Table 3
Hepatic responses by RECIST in phase 2 study [
39]
CR | 0 | 0 | 0 | 0 |
PR | 10 | 1 | 3 | 0 |
SD | 6 | 4 | 1 | 4 |
PD | 3 | 1 | 0 | 5 |
Not available | 5 | 2 | 0 | 8 |
In the phase 3 study, 44 patients were randomized to CS-PHP and 49 to BAC [
39]. The majority of patients (81.6%) in the BAC group received active treatment (most frequently with temozolamide) whereas 18.4% of patients received only supportive care. A clinically meaningful and statistically significant improvement in hPFS was observed in the CS-PHP group compared to the BAC group. Median hPFS was 1.64 months (95% CI 1.48–2.92) in the BAC group compared to 7.03 months (95% CI 5.22–9.66) in the CS-PHP group (
P < 0.001). Additionally, there was a statistically significant (
P < 0.0001) improvement in the hOR rate with PHP (36.4%) compared to BAC (2.0%). Median OS was similar in the CS-PHP and BAC groups; however, these results are confounded by the high number of BAC patients (57.1%) who crossed over to CS-PHP treatment. Of the 49 patients originally assigned to BAC, 28 had hepatic disease progression and crossed over to receive CS-PHP. A post hoc analysis examined outcomes in these patients compared to those in the BAC group who had not crossed over to CS-PHP and those originally assigned to CS-PHP [
40]. The baseline characteristics of the crossover group were comparable to the groups who received BAC only and those who were initially randomized to CS-PHP [
39]. The analysis of outcomes in this post hoc analysis showed that the efficacy of CS-PHP in the crossover group was similar to that in the group initially randomized to this therapy. The median hPFS was 8.0 in the CS-PHP group and 1.6 in the BAC group that had not crossed over to CS-PHP (
P < 0.0001). The crossover group had an hPFS of 8.8 months, which was comparable to that in the group initially treated with CS-PHP. The median OS was 9.8 months in the CS-PHP group as opposed to 4.1 months in the BAC-only group and 15.3 months in the crossover group. As was seen in the phase 2 study, the toxicity profile in the phase 3 study was characterized by adverse events related to bone marrow suppression, including thrombocytopenia, neutropenia, and anemia. Most of these events were not associated with clinical sequelae.
Retrospective Studies
In addition to the results of the clinical trial program, several retrospective studies reported outcomes data for CS-PHP with melphalan (summarized in Table
4). A total of four noncomparative studies were conducted [
41‐
44]. One of the noncomparative studies enrolled 13 patients [
44], 10 of whom were also included in a separate comparative retrospective analysis [
45]. In addition, two case reports were published [
46,
47]. All of the studies reported hepatic response data; two of the studies also reported toxicity data [
41,
43].
Table 4
Outcomes data for CS-PHP in the literature [
33‐
35,
37‐
39]
| 13 | Ocular melanoma (8) Cutaneous melanoma (3) Breast cancer (1) Cholangiocarcinoma (1) | CS-PHP (13)c
| Overall response rate: 58% 1 CR (CCA) 6 PR (3 ocular and 3 cutaneous) 5 SD (3 ocular, 1 breast, 1 gastric) 0 PD |
| 11 | CRC (6) Ocular melanoma (5) | CS-PHP (8)d
| Overall response rate: 75% 6 PR (2 colorectal, 4 ocular) 2 PD |
| 20 | Ocular melanoma (20) | CS-PHP (20) | Overall response rate: 70% 2 CR 13 PR 2 SD 3 PD |
| 30e
| Ocular melanoma (16) Cutaneous melanoma (13) Unknown (1) | Y90 (6) CS-PHP (10) CE (12) | hPFS CS-PHP vs Y90 RR 0.08; P < 0.001 PHP vs CE RR 0.13; P = 0.008 CE vs Y90 RR 0.64; P = 0.44 OS CS-PHP vs Y90 RR 0.05; P = 0.03 PHP vs CE RR 0.51; P = 0.37 CE vs Y90 RR 0.09; P = 0.06 |
| 1 | Leiomyosarcoma | CS-PHP (1) | 1 SD 0 PD |
| 1 | Solid pseudopapillary neoplasm of the pancreas | CS-PHP (1) | 1 PR 0 PD |
In the noncomparative studies of CS-PHP with melphalan for the treatment of unresectable hepatic metastases, patients had a variety of primary tumor types, including ocular melanoma, cutaneous melanoma, CRC, leiomyosarcoma, breast cancer, cholangiocarcinoma, and gastric cancer (Table
4) [
41‐
44]. Among the 54 patients in these four studies, hepatic response rates by RECIST criteria were 58%, 75%, 70%, and 61.5%, respectively. Hepatic responses were seen in patients with cholangiocarcinoma, CRC, ocular melanoma, and cutaneous melanoma, with complete responses in one patient with cholangiocarcinoma and two patients with ocular melanoma. Stable disease was also observed with CS-PHP in patients with ocular melanoma, cutaneous melanoma, melanoma with unknown primary, leiomyosarcoma, breast cancer, and gastric cancer.
Toxicity data were reported in the noncomparative study by Vogl et al. [
41]. Toxicities following CS-PHP were consistent with the toxicity profile seen in the clinical trials of CS-PHP with melphalan. The most common adverse effects were hematologic events (thrombocytopenia, anemia, neutropenia), which were managed effectively with supportive measures. Three patients were initially treated with the first-generation filter, then switched to the second-generation filter, providing an opportunity for a comparison of toxicity profiles with the two systems. Toxicity was less severe and patients required fewer supportive measures (i.e., no transfusions, shorter courses of colony stimulating factors) with the second-generation filter than the first-generation filter.
The comparative study was a retrospective evaluation of outcomes at a single institution in a small number of patients (
N = 30) with unresectable hepatic metastases from ocular melanoma, cutaneous melanoma, or an unknown primary tumor who received a liver-directed therapy between 2008 and 2014 (Table
4) [
37]. Liver-directed therapies included yttrium, chemoembolization, and CS-PHP. One patient was treated with yttrium after CS-PHP and one patient was treated with CS-PHP after chemoembolization; both of these patients were excluded from the efficacy analyses. Kaplan–Meier survival estimates, log-rank test, and multivariate Cox regression analyses were used to relate patient, tumor, and treatment variables to hPFS and OS.
There were no differences between the yttrium, chemoembolization, and CS-PHP groups with regard to age, adjuvant therapy, prior regional hepatic treatment, or complications following treatment. Extrahepatic disease was more prevalent in the chemoembolization group (P = 0.004) compared with the yttrium and CS-PHP groups. The ECOG score trended lower in the CS-PHP group (P = 0.051) compared with the yttrium and chemoembolization groups.
Median hPFS was significantly (
P = 0.002) longer with CS-PHP (310 days) than with yttrium (54 days) and chemoembolization (80 days) [
36]. Median hPFS was also significantly longer with CS-PHP versus yttrium (
P < 0.001) and CS-PHP versus chemoembolization (
P = 0.008), but not yttrium versus chemoembolization (
P = 0.44). A higher ECOG score (
P = 0.01) and a greater tumor burden (
P = 0.03) were correlated with a shorter duration of hPFS. Median OS was longer with CS-PHP (736 days) than with yttrium (285 days) and chemoembolization (265 days); this difference was significant for CS-PHP versus yttrium (
P = 0.03). Neither ECOG score nor tumor burden were significant predictors of OS.
Case Reports
Two case reports for CS-PHP with melphalan have been published (Table
4) [
46,
47]. Hofman et al. reported the case of a 40-year-old woman with unresectable hepatic metastases from a solid pseudopapillary neoplasm of the pancreas who had progressive liver disease after 3 months of systemic chemotherapy (gemcitabine and cisplatin) [
47]. CS-PHP was performed twice within 8 weeks and a partial response was observed. The patient recovered rapidly after each CS-PHP procedure. Grade 3 leukopenia was seen after the second procedure and was effectively managed with granulocyte colony stimulating factor. No other toxicities were evident.
Deneve et al. described the case of a 66-year-old woman with isolated bilobar unresectable hepatic metastases from leiomyosarcoma [
46]. Four target hepatic lesions were identified and monitored to assess treatment response. The patient underwent four CS-PHP procedures with melphalan. A 25% reduction in the size of the largest target lesion was observed, and the hPFS was 16 months. With the first CS-PHP procedure, the patient had mild bone marrow suppression, including thrombocytopenia and neutropenia, which were managed with filgrastim and platelet transfusion, respectively. Minimal toxicity and a more rapid recovery were seen with the second CS-PHP procedure.
Post-approval Experience with CS-PHP in Europe
As of July 31, 2016, 186 patients in the EU had received a total of 321 CS-PHP treatments (Table
5). Most procedures were performed for patients with liver metastases from ocular melanoma. The majority of procedures were performed in Germany (75 procedures total in 11 hospitals), the UK (49 procedures total in four hospitals), and the Netherlands (33 procedures total in two hospitals). CS-PHP was also performed in Italy (12 procedures total in two hospitals), France (nine procedures total in two hospitals), Spain (six procedures total in two hospitals), Ireland (one procedure total in one hospital), and Turkey (one procedure in one hospital).
Table 5
Number of CS-PHP treatments in Europe by tumour type
Ocular melanoma | 213 |
Cutaneous melanoma | 9 |
Cholangiocarcinoma | 41 |
Breast cancer | 5 |
Hepatocellular carcinoma | 13 |
NET | 4 |
Anal mucosal melanoma | 1 |
Pancreatic cancer | 11 |
Colorectal cancer | 20 |
Sarcoma | 1 |
Gastric cancer | 1 |
Endometrium cancer | 1 |
Prostate | 1 |
Total | 321 |
An EU registry has been initiated to collect safety, efficacy, and resource utilization data for patients who have received CS-PHP for treatment of an unresectable hepatic malignancy. Delcath is contacting its list of authorized customer hospitals that have been supplied the Hepatic CHEMOSAT® Delivery System to request that they identify patients who have received or who will be receiving CS-PHP treatment for inclusion in this registry. Efficacy data that will be collected include hepatic response to treatment; time to partial response or complete response; time to liver metastasis progression; time to extrahepatic disease progression, and overall survival. Safety data that will be collected include laboratory test results; length of postoperative stay; blood product use; hospital admission and reason for admission within 30 days following CS-PHP; disease- and treatment-related adverse events; supportive care (i.e., growth factors and antibiotics); performance status; tumor-related symptoms; and quality of life. The registry will end when data for 200 patients have been accrued.